Word: leukemias
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
AILING. CORINA MORARIU, 23, former No. 1 ranked women's doubles player and 1999 Wimbledon women's doubles champion with Lindsay Davenport; with a rare form of leukemia; in Florida. Doctors estimated that Morariu had been sick for months, even while playing the grueling WTA tour...
...February of last year, Victoria Reiter, 63, figured she had only a few months to live. A writer and translator living in Manhattan, she was suffering from chronic myeloid leukemia, an especially deadly form of blood cancer. The only treatment available was interferon, an immune-system booster that wasn't really working and that made her violently ill. Reiter had spent most of 1999 in bed, too sick to read, to walk, to do much of anything--although she had managed to put together lists dividing her possessions between her two daughters...
Then she went on an experimental drug called Gleevec, and within weeks everything changed. "All my energy started coming back," she says. "Suddenly I could read. I could take a walk." By August, tests showed her bone marrow was clear of leukemia cells; in December, she took up the Argentine tango. She still has the lists of what her daughters will get, but, she exults, "They're not going...
Those are only two drugs that keep EGF from doing its job. Gleevec, which reversed Reiter's and Ferber's leukemia so dramatically, is another; so is Tarceva, a drug from OSI Pharmaceuticals in Uniondale, N.Y., which is showing promise against some lung tumors as well as head and neck cancers. Neither of these compounds keeps EGF from docking with cells; instead, each worms its way inside the cells, where it intercepts growth messages percolating in from the surface. Astra Zeneca, headquartered in London, is testing a similar compound, Iressa, against some lung, stomach and prostate cancers...
...Cambridge, Mass., Millennium Pharmaceuticals is focusing on proteins called proteasomes, which evidently play a role in giving cancer cells unnaturally long lives. The company is in Phase II trials with LDP341, a proteasome-inhibiting substance that is showing promise against multiple myeloma and chronic lymphocytic leukemia. Phase I studies on the top five solid tumors (breast, pancreatic, prostate, lung and colon) are under way, and at this point the inhibitor seems to be working--at least in mice...